Saturday, 17 August 2024
by BD Banks
Shares of Emergent BioSolutions (NYSE: EBS) were skyrocketing 19.5% higher as of 11:09 a.m. ET on Friday after rising as much as 34.1% earlier in the day. The big gain came after the European Centre for Disease Prevention and Control raised its risk level for mpox to “moderate” from “low.” The decision followed the confirmation of a case of mpox infection in Sweden.
On Wednesday, the World Health Organization declared a global public health emergency after an outbreak of mpox in Africa. The first cases were reported in the Democratic Republic of Congo, but the virus quickly spread to other African countries.
The only approved vaccine for preventing mpox is made by Bavarian Nordic. However, the U.S. Centers for Disease Control and Prevention (CDC) has also recommended Emergent BioSolutions’ ACAM2000 vaccine for preventing mpox.
ACAM2000 is currently approved only for preventing smallpox. It is also recommended by the Advisory Committee on Immunization Practices for some people at risk of exposure to orthopoxvirus infections. Mpox is an orthopoxvirus similar to smallpox.
I don’t think Emergent BioSolutions stock is a buy because of the mpox outbreak. The company could experience a temporary sales bump for ACAM2000, but there’s no reason at this point to expect a significant sustained impact.
In the meantime, Emergent BioSolutions is still trying to turn its business around, with revenue sinking 25% year over year in the second quarter of 2024. Other healthcare stocks offer better risk-reward propositions, in my view.
Before you buy stock in Emergent BioSolutions, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Emergent BioSolutions wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Nvidia made this list on April 15, 2005… if you invested $1,000 at the time of our recommendation, you’d have $752,835!*
Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock Advisor service has more than quadrupled the return of S&P 500 since 2002*.
*Stock Advisor returns as of August 12, 2024
Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Emergent BioSolutions. The Motley Fool has a disclosure policy.